Skip to Content


In the US, Maraviroc (maraviroc systemic) is a member of the drug class chemokine receptor antagonist and is used to treat HIV Infection.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Antiviral agent

Treatment of HIV infection

CCR5 antagonist

Chemical Names

(S)-4,4-Difluorcyclohexancarbonsäure-{(1R,3s,5S)-3-[3-(3-isopropyl-5-metyl-[1,2,4]triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropyl}amid (IUPAC)

4,4-Difluoro-N-[(1S)-3-{(1R,3s,5S)-3-[3-metyl-5-(propan-2-yl)4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]octan-8-yl}-1-phenylpropyl]cyclohexanecarboxamide (WHO)

Cyclohexanecarboxamide, 4,4-difluoro-N-((1S)-3-((3-exo)-3-(3-metyl-5-(1-metyletyl)-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)-

Foreign Names

  • Maravirocum (Latin)
  • Maraviroc (German)
  • Maraviroc (French)
  • Maraviroc (Spanish)

Generic Names

  • Maraviroc (OS: BAN, JAN)
  • UK-382055 (IS)
  • UK-395859 (IS)
  • UK-408030 (IS)
  • UK-418526 (IS)
  • UK-427857 (IS: Pfizer)

Brand Names

  • Celsentri
    GlaxoSmithKline, Chile; GlaxoSmithKline, Colombia; GlaxoSmithKline, Costa Rica; GlaxoSmithKline, Denmark; GlaxoSmithKline, Finland; GlaxoSmithKline, Guatemala; GlaxoSmithKline, Hong Kong; GlaxoSmithKline, Honduras; GlaxoSmithKline, Croatia (Hrvatska); GlaxoSmithKline, Singapore; GlaxoSmithKline, El Salvador; GlaxoSmithKline, Taiwan; GlaxoSmithKline, South Africa; GlaxoSmithKline & ViiV Healthcare, Thailand; Haemato Pharm, Austria; Pfizer, Argentina; Pfizer, China; Pfizer, Czech Republic; Pfizer, Israel; Pfizer, Oman; Pfizer, Romania; Pfizer, Serbia; Pfizer Luxembourg, Bosnia & Herzegowina; ViiV, Australia; ViiV, Belgium; ViiV, Hungary; ViiV Healthcare, Austria; ViiV Healthcare, Switzerland; ViiV Healthcare, France; ViiV Healthcare, Greece; ViiV Healthcare, Ireland; ViiV Healthcare, Italy; ViiV Healthcare, Japan; ViiV Healthcare, Lithuania; ViiV Healthcare, Norway; ViiV Healthcare, Poland; Viiv Healthcare S.L., Spain; Viiv Healthcare UK, Cyprus; ViiV Healthcare UK Limited, Iceland; ViiV Healthcare ULC, Canada
    GlaxoSmithKline, Sweden; ViiV Healthcare, Germany
  • Selzentry
    GlaxoSmithKline, Mexico; ViiV Healthcare, United States


BANBritish Approved Name
IUPACInternational Union of Pure and Applied Chemistry
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.